Quarterly ResultMay 15, 2026, 04:44 PM
Northwest Biotherapeutics Reports Q1 Net Loss of $3.1M; Going Concern Doubt
AI Summary
Northwest Biotherapeutics reported a net loss of $3.1 million for Q1 2026, a significant improvement from $19.3 million in Q1 2025. Revenues increased to $0.5 million, while operating expenses decreased. Despite these improvements, the company disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash flow deficits. The Marketing Authorization Application for DCVax®-L for glioblastoma is currently under MHRA review in the U.K.
Key Highlights
- Substantial doubt about the company's ability to continue as a going concern.
- Net loss significantly improved to $3.1 million in Q1 2026 from $19.3 million in Q1 2025.
- Total revenues increased to $0.5 million in Q1 2026 from $0.4 million in Q1 2025.
- Research and development expenses decreased to $4.9 million from $8.4 million year-over-year.
- General and administrative expenses decreased to $6.5 million from $9.3 million year-over-year.
- Cash and cash equivalents decreased to $1.8 million as of March 31, 2026, from $3.0 million.
- Contingent payable derivative liability reduced to zero as performance condition is not probable.
- 22.9 million stock options cancelled following litigation settlement on March 16, 2026.
Price Impact
More from NWBO